dc.contributor.author | Yozgat, Ahmet | |
dc.contributor.author | Kasapoğlu, Benan | |
dc.contributor.author | Can, Güray | |
dc.contributor.author | Tanoğlu, Alpaslan | |
dc.contributor.author | Sakin, Yusuf Serdar | |
dc.contributor.author | Yalçın, Kadir Serkan | |
dc.contributor.author | Gürler, Müjgan | |
dc.date.accessioned | 2021-10-05T09:30:51Z | |
dc.date.available | 2021-10-05T09:30:51Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Yozgat, A., Kasapoglu, B., Can, G., Tanoglu, A., Sakin, Y. S., Yalcin, K. S., Gurler, M., Kaplan, M., Kaban, M. G., Kirsoy, M., Kara, U., & Kekilli, M. (2021). Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19. Turkish Journal of Medical Sciences, 51(4), 1675–1681. https://doi.org/10.3906/sag-2103-80 | |
dc.identifier.issn | 1300-0144 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14065/2509 | |
dc.identifier.uri | https://doi.org/10.3906/sag-2103-80 | |
dc.description.abstract | Background and aim: The aim of this study is to evaluate whether the long-term (?4 weeks) use of proton pump inhibitors (PPIs) is arisk factor for intubation requirement and mortality in patients hospitalized for COVID-19.Materials and methods: In this multicentric retrospective study, a total of 382 adult patients (?18 years of age) with confirmedCOVID-19 who were hospitalized for treatment were enrolled. The patients were divided into two groups according to the periodsduring which they used PPIs: the first group included patients who were not on PPI treatment, and the second group included thosewho have used PPIs for more than 4 weeks.Results: The study participants were grouped according to their PPI usage history over the last 6 months. In total, 291 patients did notuse any type of PPI over the last 6 months, and 91 patients used PPIs for more than 4 weeks. Older age (HR: 1.047, 95% CI: 1.026–1.068),current smoking (HR: 2.590, 95% CI: 1.334–5.025), and PPI therapy for more than 4 weeks (HR: 1.83, 95% CI: 1.06–2.41) were foundto be independent risk factors for mortality.Conclusion: The results obtained in this study show that using PPIs for more than 4 weeks is associated with negative outcomes forpatients with COVID-19. Patients receiving PPI therapy should be evaluated more carefully if they are hospitalized for COVID-19treatment. | en_US |
dc.language.iso | eng | en_US |
dc.relation.ispartof | Turkish Journal of Medical Sciences | |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Covid-19 | en_US |
dc.subject | Proton pump inhibitors | en_US |
dc.subject | Mortality | en_US |
dc.title | Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19 | en_US |
dc.type | article | en_US |
dc.department | Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Gastroenteroloji | en_US |
dc.institutionauthor | Yozgat, Ahmet | |
dc.identifier.doi | 10.3906/sag-2103-80 | |
dc.identifier.volume | 51 | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 1675 | |
dc.identifier.endpage | 1681 | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorscopusid | 55994128200 | |
dc.authorscopusid | 1624535300 | |
dc.authorscopusid | 56432433500 | |
dc.authorscopusid | 22836913800 | |
dc.authorscopusid | 55064480300 | |
dc.authorscopusid | 56946575700 | |
dc.authorscopusid | 24177878100 | |
dc.identifier.wosquality | Q3 | |
dc.identifier.wos | WOS:000691544700010 | |
dc.identifier.scopus | 2-s2.0-85114232754 | |
dc.identifier.trdizinid | 479976 | |
dc.identifier.pmid | 34110723 | |